Eureka Therapeutics, Memorial Sloan Kettering, Juno Therapeutics deal

Memorial Sloan and Eureka granted Juno exclusive, worldwide rights to binding domains against three multiple myeloma (MM) targets. Juno will incorporate the targets into chimeric antigen receptor (CAR...